3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Glioblastoma
24
Glioma
13
Astrocytoma
9
Brain Neoplasms
8
Neuroblastoma
6
Neoplasms
6
Gliosarcoma
6
Sarcoma, Ewing
4
Medulloblastoma
4
Rhabdomyosarcoma
3
Recurrence
3
Oligodendroglioma
3
Diffuse Intrinsic Pontine Glioma
3
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Interventions
pembrolizumab
23
Carboplatin
23
Paclitaxel
17
Specimen Handling
15
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
10
Biopsy
10
Taxes
7
Capecitabine
7
Nivolumab
6
130-nm albumin-bound paclitaxel
6
sacituzumab govitecan
5
Gemcitabine
5
Doxorubicin
5
Albumin-Bound Paclitaxel
5
Fulvestrant
4
olaparib
3
fludarabine
3
eribulin
3
durvalumab
3
atezolizumab
3
Letrozole
3
Epirubicin
3
Bevacizumab
3
veliparib
2
poly ICLC
2
pertuzumab
2
aldesleukin
2
abemaciclib
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Temozolomide
×
30 days
×
Clear all
No trials found.